iTeos Therapeutics, Inc. (ITOS)
NASDAQ
Market Cap
$543.29M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
324 of 809
Rank in Industry
195 of 445
Largest Insider Buys in Sector
ITOS Stock Price History Chart
ITOS Stock Performance
About iTeos Therapeutics, Inc.
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.
Insider Activity of iTeos Therapeutics, Inc.
Over the last 12 months, insiders at iTeos Therapeutics, Inc. have bought $41,850 and sold $5.69M worth of iTeos Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at iTeos Therapeutics, Inc. have bought $52.49M and sold $63.54M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Gall Matthew (Chief Financial Officer) — $41,850.
The last purchase of 5,000 shares for transaction amount of $41,850 was made by Gall Matthew (Chief Financial Officer) on 2023‑10‑12.
List of Insider Buy and Sell Transactions, iTeos Therapeutics, Inc.
| 2023-10-12 | Gall Matthew | Chief Financial Officer | 5,000 0.0136% | $8.37 | $41,850 | +26.14% | ||
| 2023-08-23 | Sale | Boxer Capital, LLC | 350,000 1.1785% | $16.26 | $5.69M | -18.81% | ||
| 2022-06-08 | Sale | Hallal David | 1,171 0.0033% | $19.51 | $22,846 | -3.14% | ||
| 2022-05-09 | Sale | Davis Aaron I. | 337,109 0.7412% | $18.25 | $6.15M | -17.43% | ||
| 2022-04-28 | Sale | Davis Aaron I. | 115,000 0.3152% | $27.01 | $3.11M | -29.86% | ||
| 2022-04-18 | Sale | Detheux Michel | Chief Executive Officer | 11,467 0.0326% | $31.87 | $365,453 | -37.63% | |
| 2022-03-22 | Davis Aaron I. | 20,000 0.0553% | $32.85 | $656,980 | -39.63% | |||
| 2022-03-21 | Sale | Detheux Michel | Chief Executive Officer | 5,822 0.0167% | $33.44 | $194,688 | -38.51% | |
| 2022-03-17 | Sale | LEWIS JOSEPH | 575,201 1.5917% | $35.25 | $20.28M | -43.47% | ||
| 2022-03-11 | Sale | Lager Joanne Jenkins | Chief Medical Officer | 3,500 0.0099% | $36.01 | $126,035 | -43.21% | |
| 2022-03-01 | Sale | McGrath Yvonne | Chief Scientific Officer | 10,000 0.0283% | $36.76 | $367,570 | -43.58% | |
| 2022-02-23 | Sale | Detheux Michel | Chief Executive Officer | 14,500 0.0414% | $34.34 | $497,905 | -38.35% | |
| 2022-02-11 | Sale | Lager Joanne Jenkins | Chief Medical Officer | 3,500 0.0101% | $35.85 | $125,459 | -40.32% | |
| 2022-01-25 | Sale | Detheux Michel | Chief Executive Officer | 14,500 0.0403% | $35.68 | $517,378 | -40.58% | |
| 2022-01-14 | Sale | Lager Joanne Jenkins | Chief Medical Officer | 3,500 0.0098% | $39.32 | $137,614 | -45.75% | |
| 2022-01-05 | Sale | GADICKE ANSBERT | 10 percent owner | 30,347 0.0856% | $42.03 | $1.28M | -46.62% | |
| 2022-01-05 | Sale | MPM BIOVENTURES 2018, L.P. | 10 percent owner | 18,135 0.0512% | $42.03 | $762,214 | -46.62% | |
| 2022-01-05 | Sale | MPM BioVentures 2014, L.P. | 10 percent owner | 18,135 0.0512% | $42.03 | $762,214 | -46.62% | |
| 2022-01-04 | Sale | GADICKE ANSBERT | 10 percent owner | 215,122 0.6156% | $42.66 | $9.18M | -46.05% | |
| 2022-01-04 | Sale | MPM BIOVENTURES 2018, L.P. | 10 percent owner | 128,550 0.3679% | $42.66 | $5.48M | -46.05% |
Insider Historical Profitability
28.35%
| Boxer Capital, LLC | 1804058 5.0414% | $15.04 | 1 | 3 | +45.66% | |
| Gall Matthew | Chief Financial Officer | 19429 0.0543% | $15.04 | 2 | 1 | +9.8% |
| GADICKE ANSBERT | 10 percent owner | 4484728 12.5324% | $15.04 | 1 | 43 | +45.66% |
| RA CAPITAL MANAGEMENT, L.P. | 10 percent owner | 4417259 12.3439% | $15.04 | 1 | 0 | +45.66% |
| LEWIS JOSEPH | 3142058 8.7804% | $15.04 | 0 | 1 | ||
| MPM BIOVENTURES 2018, L.P. | 10 percent owner | 2738785 7.6534% | $15.04 | 0 | 43 | |
| MPM BioVentures 2014, L.P. | 10 percent owner | 2738785 7.6534% | $15.04 | 1 | 43 | +45.66% |
| Davis Aaron I. | 2154058 6.0194% | $15.04 | 2 | 2 | +3.01% | |
| Detheux Michel | Chief Executive Officer | 26296 0.0735% | $15.04 | 0 | 25 | |
| Hallal David | 0 0% | $15.04 | 0 | 2 | ||
| McGrath Yvonne | Chief Scientific Officer | 0 0% | $15.04 | 0 | 6 | |
| Biniszkiewicz Detlev | director | 0 0% | $15.04 | 0 | 1 | |
| Lager Joanne Jenkins | Chief Medical Officer | 0 0% | $15.04 | 0 | 7 |
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
| RA Capital Management, L.P. | $60.25M | 12.23 | 4.42M | 0% | +$0 | 0.06 | |
| BlackRock | $56.13M | 11.39 | 4.11M | -3.45% | -$2M | <0.01 | |
| MPM Asset Management LLC | $37.36M | 7.58 | 2.74M | 0% | +$0 | 15.24 | |
| Ecor1 Capital Llc | $27.27M | 5.54 | 2M | +79.3% | +$12.06M | 0.69 | |
| Boxer Capital, LLC | $24.61M | 4.99 | 1.8M | 0% | +$0 | 1.23 | |
| Bioimpact Capital Llc | $23.81M | 4.83 | 1.75M | 0% | +$0 | 3.86 | |
| Morgan Stanley | $22.27M | 4.52 | 1.63M | +44.27% | +$6.83M | <0.01 | |
| The Vanguard Group | $20.47M | 4.15 | 1.5M | +0.65% | +$131,762.40 | <0.0001 | |
| Citadel Advisors LLC | $15.94M | 3.24 | 1.17M | +3.44% | +$530,268.61 | 0.01 | |
| Braidwell Lp | $15.85M | 3.22 | 1.16M | New | +$15.85M | 0.89 | |
| Millennium Management LLC | $12.04M | 2.44 | 882,981 | -8.73% | -$1.15M | 0.01 | |
| Dimensional Fund Advisors | $10.79M | 2.19 | 791,170 | +2.33% | +$245,888.29 | <0.01 | |
| Deerfield Management | $9.86M | 2 | 723,000 | 0% | +$0 | 0.19 | |
| Renaissance Technologies | $9.78M | 1.99 | 717,300 | +2.63% | +$250,976.72 | 0.02 | |
| Goldman Sachs | $9.77M | 1.98 | 716,257 | -3.48% | -$352,062.02 | <0.01 | |
| 683 Capital Management Llc | $9.75M | 1.98 | 715,000 | 0% | +$0 | 1.1 | |
| Geode Capital Management | $7.96M | 1.62 | 583,520 | +2.58% | +$199,985.85 | <0.01 | |
| State Street | $7.88M | 1.6 | 577,545 | +4.71% | +$354,503.61 | <0.0001 | |
| Jacobs Levy Equity Management | $6.88M | 1.4 | 504,545 | -5.63% | -$410,782.25 | 0.03 | |
| Saturn V Capital Management Llc | $5.28M | 1.07 | 387,095 | -53.26% | -$6.02M | 2.12 | |
| Nuveen | $5.06M | 1.03 | 371,101 | +91.88% | +$2.42M | <0.01 | |
| Barclays | $4.72M | 0.96 | 346,419 | +10.83% | +$461,548.80 | <0.01 | |
| Citigroup | $4.04M | 0.82 | 295,984 | -14.16% | -$665,877.56 | <0.01 | |
| Northern Trust | $3.41M | 0.69 | 249,802 | -2.74% | -$96,134.74 | <0.01 | |
| Acadian Asset Management | $3.34M | 0.68 | 244,712 | New | +$3.34M | 0.01 | |
| Prudential Financial | $3.3M | 0.67 | 241,891 | -29.48% | -$1.38M | 0.01 | |
| HERITAGE ASSET MANAGEMENT INC | $3.12M | 0.65 | 233,584 | New | +$3.12M | 0.02 | |
| Charles Schwab | $2.81M | 0.57 | 205,865 | +2.14% | +$58,856.61 | <0.01 | |
| Readystate Asset Management Lp | $2.55M | 0.52 | 186,902 | +31.82% | +$615,313.97 | 0.14 | |
| Kennedy Capital Management Inc | $1.99M | 0.4 | 145,734 | New | +$1.99M | 0.04 | |
| D. E. Shaw & Co. | $1.86M | 0.38 | 136,720 | -15.63% | -$345,610.36 | <0.01 | |
| Sectoral Asset Management | $1.83M | 0.37 | 133,966 | -39.12% | -$1.17M | 0.76 | |
| Algert Global LLC | $1.74M | 0.35 | 127,270 | -1.23% | -$21,688.06 | 0.07 | |
| Panagora | $1.65M | 0.33 | 120,766 | -3.01% | -$51,081.79 | 0.01 | |
| BNY Mellon | $1.58M | 0.32 | 115,841 | -6.69% | -$113,347.95 | <0.0001 | |
| Cubist Systematic Strategies | $1.42M | 0.29 | 103,981 | -22.4% | -$409,486.49 | 0.01 | |
| Ikarian Capital LLC | $1.38M | 0.28 | 101,325 | -70.75% | -$3.34M | 0.39 | |
| DAFNA Capital Management, LLC | $1.34M | 0.27 | 98,560 | 0% | +$0 | 0.31 | |
| Victory Capital Management Inc | $1.28M | 0.26 | 93,760 | +17.5% | +$190,509.82 | <0.01 | |
| AQR Capital | $1.18M | 0.24 | 86,168 | -8.33% | -$106,828.43 | <0.01 | |
| Wellington Management Company | $1.17M | 0.24 | 85,854 | New | +$1.17M | <0.0001 | |
| Invesco | $1.15M | 0.23 | 84,559 | +128.33% | +$648,254.78 | <0.0001 | |
| J. Goldman & Company | $1.12M | 0.23 | 82,153 | New | +$1.12M | 0.05 | |
| Two Sigma | $1.09M | 0.22 | 80,052 | +194.13% | +$720,669.21 | <0.01 | |
| Ameriprise Financial | $1.07M | 0.22 | 78,784 | +8.34% | +$82,712.98 | <0.0001 | |
| Massachusetts Financial Services Co Ma | $1.03M | 0.21 | 75,678 | -0.22% | -$2,291.52 | <0.0001 | |
| UBS | $806,042.00 | 0.16 | 59,094 | +30.5% | +$188,368.36 | <0.0001 | |
| Squarepoint Ops LLC | $797,081.00 | 0.16 | 58,437 | -42.03% | -$577,817.91 | <0.01 | |
| Bridgeway Capital Management | $789,988.00 | 0.16 | 57,917 | -52.23% | -$863,589.45 | 0.02 | |
| Empowered Funds Llc | $789,988.00 | 0.16 | 57,917 | -52.23% | -$863,589.45 | 0.01 |